Infectious Disease
Cytomegalovirus (CMV) Infection
0
Pipeline Programs↗
4
Active Trials↗
1
Companies Involved↗
Cytomegalovirus (CMV) Infection is an early-stage landscape with 0 programs across 1 company. The most active players are Takeda.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
12
clinical trials
Completed5 · 42%
Recruiting2 · 17%
Terminated1 · 8%
Unknown status1 · 8%
Not yet recruiting1 · 8%
Active, not recruiting1 · 8%
Other1 · 8%
Clinical Trials
Trial Activity
12 trials
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Active, not recruiting·—·N/A·NCT01199562·153 enrolled
Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.
Not yet recruiting·MMaimónides Biomedical Research Institute of Córdoba·Phase 2·NCT06057194·90 enrolled
A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00001100·130 enrolled
Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection
Withdrawn·—·Phase 1/2·NCT02346617
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)